Moderna MRNA
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Moderna (MRNA) Business Model and Operations Summary
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Key Insights
Moderna (MRNA) Core Market Data and Business Metrics
Latest Closing Price
$27.16Market Cap
$10.59 BillionAverage Daily Trade Volume
11,497,200 SharesPrice-Earnings Ratio
-2.93Total Outstanding Shares
385.82 Million SharesCEO
Mr. Stephane BancelTotal Employees
5,800Dividend
No dividendIPO Date
December 7, 2018SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
325 Binney Street, Cambridge, MA, 02142
Historical Stock Splits
If you bought 400 shares of MRNA before July 22, 2010, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| August 3, 2017 | 1-for-10 (Reverse Split) |
| December 23, 2011 | 1-for-10 (Reverse Split) |
| July 22, 2010 | 1-for-4 (Reverse Split) |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-3.00 Billion |
| Net Cash Flow From Investing Activities | $1.95 Billion |
| Net Cash Flow From Financing Activities | $56 Million |
| Net Cash Flow | $-999 Million |
| Net Cash Flow From Operating Activities, Continuing | $-3.00 Billion |
| Net Cash Flow From Financing Activities, Continuing | $56 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit, Deferred | $-1 Million |
| Income Tax Expense/Benefit, Current | $-45 Million |
| Income Tax Expense/Benefit | $-46 Million |
| Revenues | $3.24 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Benefits Costs and Expenses | $6.84 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-3.45 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $113 Million |
| Other Comprehensive Income/Loss | $-3.45 Billion |
| Comprehensive Income/Loss Attributable To Parent | $-3.45 Billion |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Inventory | $117 Million |
| Noncurrent Assets | $6.04 Billion |
| Liabilities And Equity | $14.14 Billion |
| Other Current Liabilities | $1.49 Billion |
| Noncurrent Liabilities | $1.03 Billion |
| Other Current Assets | $7.98 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||